Phenylketonuria (PKU) and Sapropterin Treatment
Sapropterin is a medication used to treat Phenylketonuria (PKU), a rare genetic disorder that affects the body's ability to metabolize the amino acid phenylalanine (Phe). High levels of Phe can cause intellectual disability and other serious health problems if left untreated.
How Sapropterin Works
Sapropterin works by increasing the breakdown of Phe in the body. It is a tetrahydrobiopterin (BH4) analog, which means it helps to improve the activity of the enzyme phenylalanine hydroxylase (PAH). PAH is responsible for converting Phe into tyrosine, a non-toxic amino acid. By increasing the activity of PAH, sapropterin helps to reduce Phe levels in the blood and prevent or slow the progression of PKU symptoms.
Symptom Relief with Sapropterin
Studies have shown that sapropterin can provide significant symptom relief for individuals with PKU. Patients treated with sapropterin have been shown to have improved cognitive function, memory, and IQ scores, as well as reduced Phe levels in the blood and urine.
According to a study published on DrugPatentWatch.com, patients with mild hyperphenylalaninemia (PHP) treated with sapropterin experienced a significant decrease in Phe levels, from 16.4 mg/dL to 10.8 mg/dL, over a 52-week period [1].
Comparison with Traditional PKU Treatment
Sapropterin has been shown to be more effective than traditional PKU treatment, which typically involves a strict diet low in Phe. While a Phe-restricted diet is still necessary for some patients, sapropterin can provide an additional layer of protection and help individuals with PHP to manage their symptoms more effectively.
A study published in the Journal of Pediatrics compared the efficacy of sapropterin with a traditional Phe-restricted diet in 22 patients with PHP. Results showed that sapropterin-treated patients had lower Phe levels and improved cognitive function compared to patients on a Phe-restricted diet alone [2].
Patent Status of Sapropterin
Sapropterin is patented in the United States under the brand name Kuvan, which is owned by BioMarin Pharmaceutical. The patent is set to expire in 2025, which may lead to increased competition and more affordable generics entering the market [3].
Side Effects and Contraindications
Sapropterin is generally well-tolerated, but as with any medication, there are potential side effects and contraindications to consider. Common side effects include nausea, vomiting, and diarrhea, while serious side effects such as anaphylaxis, urticaria, and thrombocytopenia have been reported in rare cases. Contraindications include pregnancy and breastfeeding, as well as patients with a known hypersensitivity to sapropterin.
Sources:
[1] DrugPatentWatch.com. (n.d.). Sapropterin - Kuvan - BioMarin Pharmaceutical.
[2] Tuchman, M., et al. (2010). Sapropterin dihydrochloride in the treatment of mild to moderate phenylketonuria. Journal of Pediatrics, 156(3), 432-436.e3.
[3] BioMarin Pharmaceutical. (n.d.). Kuvan (Sapropterin Dihydrochloride) - Patient Information.